IH201

IH201 is an investigational **true human monoclonal antibody** developed by **XBiotech** for the treatment and prevention of **influenza A infections**. It is a naturally occurring human antibody-derived biologic designed to **neutralize multiple influenza strains**, with reported activity spanning seasonal strains such as **H1N1** and **H3N2** as well as pandemic and avian strains including **H5N1, H5N2, H7N9, H9N2, and H10N8**. Public descriptions indicate that IH201 has been positioned both as a standalone anti-influenza antibody candidate and as a component of **FLUVID**, an antibody combination intended for influenza and influenza-COVID-19 co-infection settings together with IH302 and an anti-COVID-19 antibody. The exact viral epitope has not been clearly disclosed in the provided material, but the therapeutic concept is broad influenza virus neutralization through antibody binding to conserved viral surface antigenic determinants.